The Latest Published COVID-19 Clinical Trial Results Boost & Strengthen the Body’s Defenses
A Powerful Proteolytic & Antioxidant Enzyme Formula for Immune Support*
Proven to Promote Immune Health*

Immune Support for a Changing World

ImmunoSEB™ is a powerful blend of proteolytic and antioxidant enzymes proven to support immune health. When used as part of a consistent daily regimen, it has been shown to have a myriad of immune health benefits. Learn more about this important formula.*

How the Immune System Works

A strong immune system is more important than ever. The responsiveness and strength of the innate and adaptive immune systems depend on a variety of factors, including our stress levels, lifestyle choices and what we put in our body. Learn more about how these crucial systems function.*

The Science Behind ImmunoSEB™

ImmunoSEB™ promotes a healthy immune response in both the innate and adaptive immune systems. In vivo and in vitro studies, as well as a clinical trial, have shown ImmunoSEB™ is a powerful immunomodulator.

Clinical Trials & Case Series

Two clinical trials — one published in February 2021 on people with COVID-19 — and a case series evaluated the safety and efficacy of ImmunoSEB™ with promising results.*

In Vivo Studies

ImmunoSEB™ was studied in vivo in healthy and immunosuppressed animals. Antibiotic efficacy, as well as immunity markers such as T-cells and Immunoglobulin G (IgG), were evaluated.*

In Vitro Results

ImmunoSEB™ was studied in vitro on several clinically significant pathogenic fungi and bacterias, both solo and in combination with antibiotics.*

The Specialty Difference

ImmunoSEB™ is a powerful blend of proteolytic and antioxidant enzymes created by Specialty Enzymes & Probiotics™. It is manufactured in the company’s state-of-the-art facilities, which are GMP-certified by NSF International. The product and its ingredients are tested in Specialty Enzymes & Probiotics’ on-site, ISO-17025-certified laboratory, which specializes in enzyme and probiotics assays. ImmunoSEB™ is non-GMO certified by the Non-GMO Project, among the strictest accreditation bodies. This unique enzyme formula is also gluten-free, and Halal and Kosher certified.

Contact us to add ImmunoSEB™ to your product line.

References

  1. Joshi A. et. al., Screening for antifungal activity of polyenzyme preparation ImmunoSEB™-S using in vitro methods, Trends in Biosciences 6 (3), 234- 236, 2013
  2. Joshi A. et. al., In vitro evaluation of antibacterial activity of a novel polyenzyme preparation ImmunoSEB™, Trends in Biosciences 6 (2), 142 – 145, 2013.
  3. Koyana A. et. al., Augmentation by serrapeptase of tissue permeation by Cefotiam, Japanese Journal of Antibiot. 39 (3), 761 – 771, 1986.
  4. Joshi A. et. al., Determination of antimycobacterial activity of polyenzyme preparation ImmunoSEB™-S using in vitro methods, Trends in Biosciences 5 (1), 61 – 63, 2012.
  5. Mohanty K. C. et. al., Efficacy of Lysozyme – Lactoferrin as a bioenhancer (immunomodulator) in the treatment of Tuberculosis, RGUHS Journal of Medical Sciences, 2 (2), 91 – 95, 2012.
  6. See page 4 of ImmunoSEB™ White Paper, Performance in In Vivo Study (unpublished)
  1. SIQUEIROS-CENDÓN T et. al., Immunomodulatory effects of lactoferrin, Acta Pharmacologica Sinica, 35: 557–566, 2014.
  2. Giansanti F et. al., Lactoferrin from Milk: Nutraceutical and Pharmacological Properties, Pharmaceuticals, 9, 61, 2016
  3. Ragland S A et. al., From bacterial killing to immunemodulation: Recent insights into the functions of lysozyme, Pathogens 13(9), 2017.
  4. Hunghey V L, et. al., Antimicrobial Activity of Lysozyme against Bacteria Involved in Food Spoilage and Food-Borne Disease, Applied and Environmental Microbiology, Vol. 53, 9, 2165 – 2170, 1987.
  5.  Selan L et. al., Serratiopeptidase reduces the invasion of osteoblasts by Staphylococcus aureus, International Journal of Immunopathology and Pharmacology, Vol. 30(4) 423–428, 2017
  6. Tiwari M, The role of serratiopeptidase in the resolution of inflammation, Asian Journal of Pharmaceutical Sciences, Volume 12, 3, 209-215, 2017.